tutte le lezioni e le notizie relative alla didattica sono sempre condivise sulla piattaforma moodle dei vari moduli in cui insegno (https://elearning.uniroma1.it/).
Le lezioni, in questo periodo , sono svolte in modalità "blended" (in presenza e a distanza) in maniera sincrona utilizzando la piattaforma ZOOM o MEET a seconda delle modalità concordate nei vari Corsi di Laurea in cui insegno, seguendo il calendario delle lezioni fornito dal Corso di Laurea.
lunedì-venerdì dalle 15.00 alle 18.00, previo appuntamento concordato tramite e-mail.
PROF. RICCIARDA GALANDRINI
Current address: Laboratory of Immunology and Immunopathology, Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, Rome, Italy. firstname.lastname@example.org
1987 Graduated with honors in Medicine, University of Perugia. Medical license number: 2076.
1992 Specialist in Internal Medicine, maximum cum laude, University of Perugia.
1995 PhD in Experimental Medicine, University of L Aquila.
1995-1997 Post doctoral fellow - Laboratory of Immunology, Imperial Cancer Research Fundation of London.
1998-2001 University Researcher in General Pathology, Immunology, Department of Experimental Medicine, Sapienza University, Rome.
2001-2006 Assistant Professor in General Pathology, Immunology, Department of Experimental Medicine and Pathology, Sapienza University, Rome.
2006-present Full Professor of Pathology and Immunology, Department of Experimental Medicine, Sapienza University, Rome.
Research interests have been aimed at understanding the molecular mechanisms regulating the activation of NK cytolytic machinery by focusing on small G protein (rac1, Arf6)- and lipid-modifying enzymes (SHIP-1, PI5KI)-dependent signals. These studies added new insights on the signaling intermediates acting at different steps of the cytotoxic process (i.e. granule polarization vs exocytosis).
More recently, my research have been focused on the role of NK cells in tumor targeting therapeutic antibodies responses. The findings elucidated a previously unrecognized molecular mechanisms leading to the functional exhaustion of NK cells and offer a mechanistic basis of resistance to therapeutic antibodies. The studies also highlight the capability of next generation defucosylated monoclonal antibodies to potentiate immunoregulatory functions of NK cells through microRNA-mediated regulation of PI3K/mTOR pathway.
More recently, my studies have elucidated the capability of therapeutic mAbs to selectively drive the in vitro expansion and the functional activation of memory NK population.
I have been recipient of research found, in particular I have been responsible for research unit of PRIN and Ateneo projects. I am member of the Society of Natural Immunity, and of the Italian Society of Immunology, Clinical Immunology and Allergology (SIICA) and I am referee for international journals in the field of immunology and tumor immunotherapy.
I am holding a coordinator role of study program and research activities for the Medical School and for PhD Course. I am author of scientific publications on internationally ranked journals (HI=21, source: Scopus) (see the institutional repository: IRIS Sapienza, pubblicazioni Ricciarda Galandrini)